2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Neil Higgins

Session 5 – A New Paradigm in Biotech Innovation & Investment
Date: 22 July (Wednesday) 15:40 – 17:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Neil Higgins

Managing Director
Locust Walk


Neil Higgins is the Managing Director of Capital Markets at Locust Walk, where he focuses on raising capital for emerging biotech and medtech companies. Prior to joining Locust Walk, Neil spent nearly 20 years in equity sales and equity sales management positions at Bank of America, Piper Jaffray, and Jefferies. 

Neil has extensive experience in crossover, IPO and follow-on financings, particularly in the biopharma sector, as well as considerable expertise in private company marketing. Prior to his career on the sell-side, Neil practiced as a corporate attorney at two major law firms in Boston and was a law clerk to the Federal District Court in Massachusetts.  

Neil earned his undergraduate degree in History, summa cum laude, from the University of Notre Dame and his JD from the University of Virginia School of Law. Neil lives in Boston with his wife, Nathalie, and their son, Liam. In his spare time Neil enjoys music, traveling, and historical studies.  


Speech title & Synopsis

More Than Just Capital- How Asian Venture Capital Firms Add Extra Value to International Deals

The presentation discusses a number of ways in which Asia-based venture firms bring unique value to international equity financing deals, and provides a case study as an example. The presentation starts with an introduction to Locust Walk and the speaker’s Capital Markets team at Locust Walk, and mentions the recent addition of a team member from Taiwan that highlights the importance of Asia in international VC deals.
 
The presentation then discusses recent trends in international capital raising and the increasing participation by Asian venture firms in international deals, and suggests that even with a slowdown in the last 12-24 months due to trade tensions, participation by Asia-based venture firms is expected to continue to be significant.
 
The presentation then discusses the reasons why Asia-based venture firms are viewed as adding extra value, which is essentially a direct result of local market expertise. The presentation then gives several examples of how local market expertise manifests itself in international deals.
 
The presentation then walks through a recent Series A financing for a, U.S.-based company, and discusses the Asia-based syndicate and several potential benefits of the Asia-based participation in the deal.
 
The presentation then summarizes the advantages of Asia-based capital participation in international deals and suggests the value -added benefits will likely continue.